p200CUX1-regulated BMP8B inhibits the progression of acute myeloid leukemia via the MAPK signaling pathway
Medical Oncology · 2024
DOI: 10.1007/s12032-024-02398-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Oncology, 2024. Verfasst von Meng Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory of Yongchuan Hospital, Chongqing Medical University, Chongqing, 402160, China. Hauptthemen laut MEDLINE: Bone Morphogenetic Proteins, Leukemia, Myeloid, Acute, MAP Kinase Signaling System. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Key Technology Innovation Special of Key Industries of the Chongqing Science and Technology Bureau, Joint Medical Research Project of Chongqing Municipal Science and Technology Commission and Health Commission, Chongqing Education Commission Science and Technology Research Program Project.
Abstract (Originalsprache)
The full-length p200CUX1 protein encoded by the homology frame CUT-like protein (CUX1) plays an important role in tumors as a pro-oncogene or oncogene. However, its role and mechanism in acute myeloid leukemia remain unknown. p200CUX1 regulates several pathways, including the MAPK signaling pathway. Our data showed that p200CUX1 is lowly expressed in THP1 and U937 AML cell lines. Lentiviral overexpression of p200CUX1 reduced proliferation and promoted apoptosis and G0/G1 phase blockade, correlating with MAPK pathway suppression. Additionally, p200CUX1 regulated the expression of bone morphogenetic protein 8B (BMP8B), which is overexpressed in AML. Overexpression of p200CUX1 downregulated BMP8B expression and inhibited the MAPK pathway. Furthermore, BMP8B knockdown inhibited AML cell proliferation, enhanced apoptosis and the sensitivity of ATRA-induced cell differentiation, and blocked G0/G1 transition. Our findings demonstrate the pivotal function of the p200CUX1-BMP8B-MAPK axis in maintaining the viability of AML cells. Consequently, targeting p200CUX1 could represent a viable strategy in AML therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Laboratory of Yongchuan Hospital, Chongqing Medical University, Chongqing, 402160, China.
- Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China.
- Clinical Laboratory of Yongchuan Hospital, Chongqing Medical University, Chongqing, 402160, China. yulihuacool@163.com.
- Central Laboratory of Yongchuan Hospital, Chongqing Medical University, Chongqing, 402160, China. liubeizhong@cqmu.edu.cn.
- Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China. liubeizhong@cqmu.edu.cn.
Förderung
- Key Technology Innovation Special of Key Industries of the Chongqing Science and Technology Bureau
- Joint Medical Research Project of Chongqing Municipal Science and Technology Commission and Health Commission
- Chongqing Education Commission Science and Technology Research Program Project
- Chongqing Natural Science Foundation Project
Zitieren
APA
Wang, M., Zhong, L., Zhang, H., Wan, P., Chu, X., Shao, X., Chen, S., Zhou, Z., Yu, L., & Liu, B. (2024). p200CUX1-regulated BMP8B inhibits the progression of acute myeloid leukemia via the MAPK signaling pathway. Medical Oncology. https://doi.org/10.1007/s12032-024-02398-2
Vancouver
Wang M, Zhong L, Zhang H, Wan P, Chu X, Shao X, et al. p200CUX1-regulated BMP8B inhibits the progression of acute myeloid leukemia via the MAPK signaling pathway. Medical Oncology. 2024. doi:10.1007/s12032-024-02398-2
BibTeX
@article{Wang2024,
author = {Wang, Meng and Zhong, Liang and Zhang, Hongyan and Wan, Peng and Chu, Xuan and Shao, Xin and Chen, Shuyu and Zhou, Ziwei and Yu, Lihua and Liu, Beizhong},
title = {p200CUX1-regulated BMP8B inhibits the progression of acute myeloid leukemia via the MAPK signaling pathway},
journal = {Medical Oncology},
year = {2024},
doi = {10.1007/s12032-024-02398-2}
}
EUVIMED